Taiwan
· Delayed Price · Currency is TWD Pharmosa Biopharm Statistics
Total Valuation
Pharmosa Biopharm has a market cap or net worth of TWD 6.87 billion. The enterprise value is 5.38 billion.
| Market Cap | 6.87B |
| Enterprise Value | 5.38B |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmosa Biopharm has 129.09 million shares outstanding. The number of shares has increased by 13.07% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 129.09M |
| Shares Change (YoY) | +13.07% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 8.57% |
| Owned by Institutions (%) | 3.03% |
| Float | 76.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 130.01 |
| PB Ratio | 3.61 |
| P/TBV Ratio | 3.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.35 |
| EV / Sales | 106.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.82 |
Financial Position
The company has a current ratio of 25.20, with a Debt / Equity ratio of 0.06.
| Current Ratio | 25.20 |
| Quick Ratio | 24.55 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -105.43 |
Financial Efficiency
Return on equity (ROE) is -18.71% and return on invested capital (ROIC) is -11.85%.
| Return on Equity (ROE) | -18.71% |
| Return on Assets (ROA) | -11.52% |
| Return on Capital (ROIC) | -11.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | 2.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.22% in the last 52 weeks. The beta is 0.52, so Pharmosa Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | -40.22% |
| 50-Day Moving Average | 59.55 |
| 200-Day Moving Average | 68.69 |
| Relative Strength Index (RSI) | 31.41 |
| Average Volume (20 Days) | 122,519 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmosa Biopharm had revenue of TWD 50.52 million and -292.93 million in losses. Loss per share was -2.37.
| Revenue | 50.52M |
| Gross Profit | 13.42M |
| Operating Income | -322.84M |
| Pretax Income | -292.93M |
| Net Income | -292.93M |
| EBITDA | -312.67M |
| EBIT | -322.84M |
| Loss Per Share | -2.37 |
Balance Sheet
The company has 1.61 billion in cash and 122.00 million in debt, giving a net cash position of 1.49 billion or 11.55 per share.
| Cash & Cash Equivalents | 1.61B |
| Total Debt | 122.00M |
| Net Cash | 1.49B |
| Net Cash Per Share | 11.55 |
| Equity (Book Value) | 1.90B |
| Book Value Per Share | 14.74 |
| Working Capital | 1.61B |
Cash Flow
In the last 12 months, operating cash flow was -265.57 million and capital expenditures -189.27 million, giving a free cash flow of -454.84 million.
| Operating Cash Flow | -265.57M |
| Capital Expenditures | -189.27M |
| Free Cash Flow | -454.84M |
| FCF Per Share | -3.52 |
Margins
| Gross Margin | 26.57% |
| Operating Margin | -639.02% |
| Pretax Margin | -579.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharmosa Biopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.07% |
| Shareholder Yield | -13.07% |
| Earnings Yield | -4.46% |
| FCF Yield | -6.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmosa Biopharm has an Altman Z-Score of 33.1.
| Altman Z-Score | 33.1 |
| Piotroski F-Score | n/a |